Zelgen has been granted with five National Major Scientific Funds
More than 117 patents have been issued in USA, EU, China and other countries.
The company has filed about 312 patent applications in worldwide
Founded in 2009, Suzhou Zelgen Biopharmaceuticals Co., Ltd. (China Shanghai: 688266) is located in the Kunshan National New & High-tech District (KSND) in Jiangsu Province, China. It is a joint venture with five subsidiaries: Gensun Biopharma Inc., Shanghai Zelgen Pharma-Tech Co. Ltd., Suzhou Zelgen Biosciences Co. Ltd., Zelgen Pharmaceuticals (Zhejiang) Co. Ltd. and Zelgen Holdings Ltd. Zelgen specializes in the research and development (R&D), manufacturing, and distribution of innovative medicines. Our goal is to become a leading pharmaceutical company in China focusing on the areas of oncology, hematology, gastroenterology and auto-immune diseases. Our market strategy emphasizes China, while expanding business opportunities internationally.
Zelgen established a robust pipeline that includes multiple late clinical stage programs as well as some early clinical stage and pre-IND programs. We have successfully built a fully integrated technology platform, with capabilities in research, development, manufacturing, and commercialization for the discovery and development of both small molecule drugs and biologics. We have commercial scale manufacturing facilities for tablets/capsules of small molecule drugs and for biologics.
Zelgen has successively completed 5 National Major Scientific Funds. Zelgen has been founded with the National Innovation Fund for Small Technology Company, as well as other provincial Science and Technology Funds. The company has filed 312 patent applications worldwide, and 117 patents have been issued in USA, EU, China and other countries.
Zelgen has three R&D centers located in Suzhou Kunshan, Shanghai Zhangjiang, and Thousand Oaks, California, USA.
Zelgen has built two GMP manufacturing facilities in Kunshan, one for tablets/capsules for small molecule drugs and one for recombinant protein drugs. These facilities ensure that Zelgen has flexible manufacturing capacity, effective cost-control and competitive advantages.